Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 27, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

[Issues around diffuse glioma].

Martin J van den Bent1

  • 1Daniel den Hoed Oncologisch Centrum, Erasmus MC, Afd. Neurologie/Neuro-oncologie, the Netherlands. m.vandenbent@erasmusmc.nl

Nederlands Tijdschrift Voor Geneeskunde
|November 17, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Radiotherapy dose escalation in glioblastoma: the thin ice of of historical controls.

The Lancet. Oncology·2026
Same author

Surgical resection or bevacizumab for treatment of radiation necrosis-associated cerebral edema in patients with brain metastases: A single center experience.

Neuro-oncology advances·2026
Same author

cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas.

Neuro-oncology·2026
Same author

Gods do play dice: The activity of regorafenib in glioblastoma not confirmed.

Neuro-oncology·2026
Same author

Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target.

Neuro-oncology advances·2026
Same journal

[Insulin intoxications caused by falsified semaglutide].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Professional skepticism in medical research].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Improving mobility in painful osteoarthritis].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The effectiveness and costs of the Back At work After Surgery (BAAS) work-integrated care pathway on return to work for patients receiving knee arthroplasty].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The rise of genetic therapies: urgent moral and societal questions].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[A man with a wound on his elbow].

Nederlands tijdschrift voor geneeskunde·2026
See all related articles

Treating diffuse gliomas is challenging due to tumor heterogeneity. Targeting single molecular pathways is insufficient for effective treatment, hindering breakthroughs in diffuse glioma therapy.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer research

Background:

  • Diffuse gliomas are complex brain tumors with limited treatment progress.
  • Current treatments like nitrosourea derivatives and temozolomide have a confirmed role but limited efficacy.
  • Tumor molecular heterogeneity is a significant barrier to effective therapeutic strategies.

Purpose of the Study:

  • To explore the molecular basis of diffuse glioma treatment resistance.
  • To understand why targeting single molecular pathways has failed to yield significant breakthroughs.
  • To investigate the role of parallel molecular signaling in treatment inadequacy.

Main Methods:

  • Review of current treatment modalities for diffuse gliomas.
  • Analysis of molecular characteristics contributing to tumor heterogeneity.

More Related Videos

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
09:17

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

Published on: September 13, 2022

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Related Experiment Videos

Last Updated: May 27, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
09:17

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

Published on: September 13, 2022

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

  • Examination of signaling pathway activation in glioma cells.

    • Main Results:

    • Diffuse gliomas exhibit significant molecular heterogeneity.
    • Abnormal activation of parallel molecular signal systems is observed.
    • Inhibition of single molecular targets is inadequate for therapeutic efficacy.

    Conclusions:

    • Molecular heterogeneity is a key factor limiting diffuse glioma treatment success.
    • Targeted therapies need to address multiple parallel pathways for efficacy.
    • Further research into complex signaling networks is crucial for advancing diffuse glioma treatment.